1,504
Participants
Start Date
October 31, 2012
Primary Completion Date
January 31, 2014
Study Completion Date
January 31, 2014
Rivaroxaban (Xarelto, BAY59-7939)
Rivaroxaban 20 mg orally once daily; subjects with moderate renal impairment (ie, CrCl of 30 to 49 mL/min, inclusive) will receive the adjusted dose of 15 mg orally once daily in the study
Vitamin K antagonist (VKA)
VKA orally once daily titrated to a target international normalized ratio (INR) of 2.5 (range 2.0-3.0, inclusive); the VKA type (eg, warfarin, acenocoumarol, phenprocoumon, fluindione, etc) will be assigned by the investigator according to local treatment standards
Bruxelles - Brussel
Alberton
Soweto
Mol
København NV
Hellerup
Leuven
Hasselt
Liège
Gilly
Worcester
Somerset West
Herning
Cape Town
Cape Town
Kuils River
Viborg
Bloemfontein
New York
New York
Torino
Attica / Athens
Troy
Berlin
Buffalo
Beaver
Butler
Hershey
Granada
Doylestown
Philadelphia
Philadelphia
Wilmington
San Donato Milanese
Hamburg
Turku
Rockville
Columbia
Annapolis
San Fermo della Battaglia
Madrid
Majadahonda
Pori
Asheville
Mestre
Pamplona
Toulouse
Savannah
Daytona Beach
Jacksonville
Saint Augustine
Tallahassee
Bad Oeynhausen
Deltona
Orlando
Melbourne
Hollywood
Miami
Fort Lauderdale
Fort Lauderdale
Pessac
Clearwater
Lakeland
Mobile
Tours
Nashville
Nashville
Johnson City
Jyväskylä
Mönchengladbach
Toledo
Cleveland
Cantan
Mansfield
Essen
Wausau
Vandœuvre-lès-Nancy
Thessaloniki
Mainz
Rapid City
Lille
Elk Grove Village
Ancona
Joliet
Aurora
Frankfurt am Main
Chicago
Chicago
Rockford
Arras
Vaasa
Alexandroupoli
Lincoln
Acquaviva delle Fonti
Paris
Paris
Paris
Dallas
Tyler
Austin
Freiburg im Breisgau
Layton
Scottsdale
Albuquerque
North Las Vegas
Nuremberg
National City
El Cajon
East Palo Alto
Catania
Santa Rosa
Sacramento
Rovaniemi
Burien
Bellingham
Beijing
Singapore
Singapore
Shanghai
Singapore
Nanchang
Changsha
Guangzhou
Xi'an
Singapore
Campinas
Torrance
New Haven
Stamford
Bridgewater
Manalapan
Fort Sam Houston
Curitiba
Porto Alegre
Campinas
São Paulo
Edmonton
Victoria
Saint John
St. John's
Hamilton
Toronto
Montreal
Montreal
Québec
Wuhan
Changchun
Ürümqi
Shenyang
Lappeenranta
Oulu
Helsinki
Tampere
Dresden
Leipzig
Heraklion
Roma
Arnhem
Haarlem
Heerlen
Leeuwarden
Maastricht
Martinho Do Bispo
Faro
Carnaxide
Almada
Lisbon
Vila Nova de Gaia
Barcelona
Sabadell
Chesterfield
Bournemouth
Welwyn Garden City
Leicester
Nottingham
Cliftonville
London
Portsmouth
Lead Sponsor
Janssen Research & Development, LLC
INDUSTRY
Bayer
INDUSTRY